Portolan Capital Management, LLC Candel Therapeutics, Inc. Transaction History
Portolan Capital Management, LLC
- $1.32 Billion
- Q4 2024
A detailed history of Portolan Capital Management, LLC transactions in Candel Therapeutics, Inc. stock. As of the latest transaction made, Portolan Capital Management, LLC holds 753,745 shares of CADL stock, worth $6.42 Million. This represents 0.5% of its overall portfolio holdings.
Number of Shares
753,745Holding current value
$6.42 Million% of portfolio
0.5%Shares
1 transactions
Others Institutions Holding CADL
# of Institutions
71Shares Held
10.7MCall Options Held
750KPut Options Held
469K-
Baker Bros. Advisors LP New York, NY2.98MShares$25.4 Million0.29% of portfolio
-
Acorn Capital Advisors, LLC New York, NY1.94MShares$16.5 Million9.1% of portfolio
-
Northpond Ventures, LLC1.94MShares$16.5 Million48.35% of portfolio
-
Braidwell LP Stamford, CT1.6MShares$13.6 Million0.78% of portfolio
-
Vanguard Group Inc Valley Forge, PA1.34MShares$11.4 Million0.0% of portfolio
About Candel Therapeutics, Inc.
- Ticker CADL
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 28,891,900
- Market Cap $246M
- Description
- Candel Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the development immunotherapies for the cancer patients. The company develops CAN-2409, which is in Phase II clinical trails for the treatment of pancreatic cancer; Phase III clinical trials for the treatment of prostate cancer; and Phase II clinical trials for the...